These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 22146109)

  • 41. Development of a hybrid physiologically based pharmacokinetic model with drug-specific scaling factors in rat to improve prediction of human pharmacokinetics.
    Sayama H; Komura H; Kogayu M; Iwaki M
    J Pharm Sci; 2013 Nov; 102(11):4193-204. PubMed ID: 24018828
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.
    Wang J; Iyer S; Fielder PJ; Davis JD; Deng R
    Biopharm Drug Dispos; 2016 Mar; 37(2):51-65. PubMed ID: 25869767
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Preclinical drug metabolism and pharmacokinetics, and prediction of human pharmacokinetics and efficacious dose of the investigational Aurora A kinase inhibitor alisertib (MLN8237).
    Yang JJ; Li Y; Chakravarty A; Lu C; Xia CQ; Chen S; Pusalkar S; Zhang M; Ecsedy J; Manfredi MG; Wu JT; Shyu WC; Balani SK
    Drug Metab Lett; 2014 Jul; 7(2):96-104. PubMed ID: 24484538
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Allometric scaling of pharmacokinetic parameters in drug discovery: can human CL, Vss and t1/2 be predicted from in-vivo rat data?
    Caldwell GW; Masucci JA; Yan Z; Hageman W
    Eur J Drug Metab Pharmacokinet; 2004; 29(2):133-43. PubMed ID: 15230342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: prediction of plasma concentration-time profiles in human from in vivo preclinical data by using the Wajima approach.
    Vuppugalla R; Marathe P; He H; Jones RD; Yates JW; Jones HM; Gibson CR; Chien JY; Ring BJ; Adkison KK; Ku MS; Fischer V; Dutta S; Sinha VK; Björnsson T; Lavé T; Poulin P
    J Pharm Sci; 2011 Oct; 100(10):4111-26. PubMed ID: 21480234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prediction of clinical pharmacokinetic parameters of linezolid using animal data by allometric scaling: applicability for the development of novel oxazolidinones.
    Bhamidipati RK; Dravid PV; Mullangi R; Srinivas NR
    Xenobiotica; 2004 Jun; 34(6):571-9. PubMed ID: 15277016
    [TBL] [Abstract][Full Text] [Related]  

  • 47. First human study of a chimeric anti-methamphetamine monoclonal antibody in healthy volunteers.
    Stevens MW; Henry RL; Owens SM; Schutz R; Gentry WB
    MAbs; 2014; 6(6):1649-56. PubMed ID: 25484042
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predictability of plasma concentration-time curves in humans using single-species allometric scaling of chimeric mice with humanized liver.
    Sanoh S; Naritomi Y; Fujimoto M; Sato K; Kawamura A; Horiguchi A; Sugihara K; Kotake Y; Ohshita H; Tateno C; Horie T; Kitamura S; Ohta S
    Xenobiotica; 2015; 45(7):605-14. PubMed ID: 25733030
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Quantitative prediction of human pharmacokinetics for mAbs exhibiting target-mediated disposition.
    Singh AP; Krzyzanski W; Martin SW; Weber G; Betts A; Ahmad A; Abraham A; Zutshi A; Lin J; Singh P
    AAPS J; 2015 Mar; 17(2):389-99. PubMed ID: 25445845
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Toward in vitro-to-in vivo translation of monoclonal antibody pharmacokinetics: Application of a neonatal Fc receptor-mediated transcytosis assay to understand the interplaying clearance mechanisms.
    Jaramillo CAC; Belli S; Cascais AC; Dudal S; Edelmann MR; Haak M; Brun ME; Otteneder MB; Ullah M; Funk C; Schuler F; Simon S
    MAbs; 2017 Jul; 9(5):781-791. PubMed ID: 28440708
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Impact of Target-Mediated Elimination on the Dose and Regimen of Evolocumab, a Human Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9).
    Gibbs JP; Doshi S; Kuchimanchi M; Grover A; Emery MG; Dodds MG; Gibbs MA; Somaratne R; Wasserman SM; Blom D
    J Clin Pharmacol; 2017 May; 57(5):616-626. PubMed ID: 27861991
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prediction of pharmacokinetics of CS-023 (RO4908463), a novel parenteral carbapenem antibiotic, in humans using animal data.
    Shibayama T; Matsushita Y; Kurihara A; Hirota T; Ikeda T
    Xenobiotica; 2007 Jan; 37(1):91-102. PubMed ID: 17178636
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Pharmacokinetics and pharmacodynamics of a humanized monoclonal antibody to factor IX in cynomolgus monkeys.
    Benincosa LJ; Chow FS; Tobia LP; Kwok DC; Davis CB; Jusko WJ
    J Pharmacol Exp Ther; 2000 Feb; 292(2):810-6. PubMed ID: 10640322
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Human pharmacokinetic prediction of UDP-glucuronosyltransferase substrates with an animal scale-up approach.
    Deguchi T; Watanabe N; Kurihara A; Igeta K; Ikenaga H; Fusegawa K; Suzuki N; Murata S; Hirouchi M; Furuta Y; Iwasaki M; Okazaki O; Izumi T
    Drug Metab Dispos; 2011 May; 39(5):820-9. PubMed ID: 21282406
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Preclinical pharmacokinetics of MHAA4549A, a human monoclonal antibody to influenza A virus, and the prediction of its efficacious clinical dose for the treatment of patients hospitalized with influenza A.
    Gupta P; Kamath AV; Park S; Chiu H; Lutman J; Maia M; Tan MW; Xu M; Swem L; Deng R
    MAbs; 2016 Jul; 8(5):991-7. PubMed ID: 27031797
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Prediction of human pharmacokinetics of panipenem-betamipron, a new carbapenem, from animal data.
    Kurihara A; Naganuma H; Hisaoka M; Tokiwa H; Kawahara Y
    Antimicrob Agents Chemother; 1992 Sep; 36(9):1810-6. PubMed ID: 1416872
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interspecies pharmacokinetic scaling of a new carbapenem, DA-1131, in mice, rats, rabbits and dogs, and prediction of human pharmacokinetics.
    Kim SH; Kim WB; Lee MG
    Biopharm Drug Dispos; 1998 May; 19(4):231-5. PubMed ID: 9604122
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacokinetic Properties of Humanized IgG1 and IgG4 Antibodies in Preclinical Species: Translational Evaluation.
    Tabrizi M; Neupane D; Elie SE; Shankaran H; Juan V; Zhang S; Hseih S; Fayadat-Dilman L; Zhang D; Song Y; Ganti V; Judo M; Spellman D; Seghezzi W; Escandon E
    AAPS J; 2019 Mar; 21(3):39. PubMed ID: 30868312
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Prediction of clearance, volume of distribution and half-life by allometric scaling and by use of plasma concentrations predicted from pharmacokinetic constants: a comparative study.
    Mahmood I
    J Pharm Pharmacol; 1999 Aug; 51(8):905-10. PubMed ID: 10504028
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Quantitative determination of humanized monoclonal antibody rhuMAb2H7 in cynomolgus monkey serum using a Generic Immunoglobulin Pharmacokinetic (GRIP) assay.
    Yang J; Ng C; Lowman H; Chestnut R; Schofield C; Sandlund B; Ernst J; Bennett G; Quarmby V
    J Immunol Methods; 2008 Jun; 335(1-2):8-20. PubMed ID: 18402977
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.